Pfizer Limited has submitted to the Exchange outcome of the Board Meeting held on May 19, 2025.
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pfizer's Board approved its audited financial results for FY25, reporting total income of Rs. 2,453.6 crore (up ~3.4% YoY) and net profit of Rs. 767.6 crore (up ~39% YoY). Profit before tax included a one-time exceptional gain of Rs. 172.81 crore from the transfer of leasehold land and building to Zoetis Pharmaceuticals. The Board recommended a total dividend of Rs. 165 per share (1650%) comprising a Rs. 35 final dividend, a Rs. 100 special dividend marking Pfizer's 75th year in India, and a Rs. 30 special dividend linked to the land sale gain, totaling Rs. 754.84 crore. Statutory auditor B S R & Co. LLP issued an unmodified audit opinion. The 74th AGM is scheduled for July 21, 2025, via video conferencing, with record date July 9, 2025. New Cost Auditor (Kishore Bhatia & Associates) and Secretarial Auditor (Parikh & Associates, 5-year term) were also appointed.
Shareholders are set to receive a bumper Rs. 165 per share dividend, giving an attractive yield. While core profit before exceptional items grew ~14% YoY showing healthy operational performance, a large share of the net profit jump is driven by a one-time land sale gain, so underlying earnings growth is more modest. The clean audit report and special anniversary dividend may support positive sentiment around the stock.